Open AccessToripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a single-center, single-arm clinical trial (ESONICT-2)
Author(s) -
Lei Gao,
Jieming Lu,
Peipei Zhang,
Zhi-Nuan Hong,
Mingqiang Kang
Publication year - 2022
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo-22-131
Subject(s) - medicine , docetaxel , neoadjuvant therapy , adverse effect , clinical endpoint , surgery , oncology , esophagectomy , single center , esophageal cancer , clinical trial , chemotherapy , cancer , breast cancer
More and more evidence has confirmed the efficacy and safety of immunotherapy drugs, such as camrelizumab and pembrolizumab. There are several phase-I/II studies showing that toripalimab has an acceptable safety profile and promising clinical activity in patients with advanced solid tumors. To further confirm its efficacy and safety, the aim of the study was to evaluate toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom